Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Fig. 4

Study design of the CTONG 1103 (EMERGING). Abbreviations: NSCLC, non-small cell lung cancer; EBUS, endobronchial ultrasound; EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group; PD, progressive disease; ORR, object response rate, CR, complete response; PFS, progression-free survival; OS, overall survival; QOL, quality of life

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us